drugset / Trial / NCT02200146
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the study is determining the non-inferiority in the overall success rate and the safety for a combination therapy with hydroxychloroquine plus low dose glucocorticoids compared to that for high dose glucocorticoids at 3 and 9 months in patients with pulmonary sarcoidosis.
Timeline
- Start
- 2009-03
- Primary completion
- 2013-07
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 200 mg | Oral |
| Comparator | Prednisone | Other / unclassified | 0.15 mg/kg | Oral |
| Comparator | Prednisone | Other / unclassified | 0.2 mg/kg | Oral |